Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2010 Feb;15(3-4):121-6. doi: 10.1016/j.drudis.2009.11.004. Epub 2009 Nov 18.

From biomarker strategies to biomarker activities and back.

Author information

1
Translational Medicine Research Centre Singapore, Schering-Plough, 8 Biomedical Grove, Neuros #04-01, Singapore. alain.vangool@spcorp.com

Abstract

The pharmaceutical industry must find ways to improve the unacceptably high attrition rate during drug development. Clearly, pharma has moved away from treat-and-see testing of new drugs in patients, with a strong current focus on generating translational biomarkers early in the research process to enable more predictive evaluation of drug action in clinical trials. Underlying such a translational medicine approach is the intensive search for and use of high-quality biomarkers indicative of successful drug target engagement, pharmacological effects, efficacy or safety. This review outlines our rational question-based drug development strategy in which biomarker data drive decisions on which drug candidates to progress to clinical testing.

PMID:
19931413
DOI:
10.1016/j.drudis.2009.11.004
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center